SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa).
Howard Jack West
No relevant relationships to disclose
James Moon
No relevant relationships to disclose
Fred R. Hirsch
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; ImClone Systems; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Celgene; ImClone Systems; Merck; Morphotek; Syndax
Philip C Mack
No relevant relationships to disclose
Antoinette J. Wozniak
Honoraria - Genentech
Research Funding - Genentech
Derick Lau
No relevant relationships to disclose
Louis Fehrenbacher
No relevant relationships to disclose
Martin Joseph Bury
No relevant relationships to disclose
Mary Weber Redman
No relevant relationships to disclose
David R. Gandara
Consultant or Advisory Role - Genentech
Research Funding - Genentech